| Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2018: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2017: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2016: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Outline of Final Research Achievements |
Sarcopenia, age-related muscle weakness, increases the frequency of falls and fractures in elderly people, which can trigger severe muscle injury. Rapid and successful recovery from muscle injury is essential not to cause further frailty and loss of independence. We previously reported that supplementation of pro-insulin-like growth factor-II (pro-IGF-II) ameliorates age-related inefficient regenerative response. However, it is expected to develop a more safety and specific therapeutic strategy for clinical application due to the tumor promoting activity of pro-IGF-II. In this study, we analyzed pro-IGF-II signal in mesenchymal progenitors and found the candidate factors that suppress adipogenic differentiation and do not have tumor promoting activity. Administration of the candidate factors could be the effective therapeutic strategy for muscle injury in elderly people.
|
